Translated title of the contribution: Clinical experience with Felbamate in paediatric age

F. Vigevano, M. R. Cilio, L. Antonini

Research output: Contribution to journalArticlepeer-review


Felbamate (FBM) is a new antiepileptic drug that has been evaluated in the Lennox-Gastaut Syndrome (LGS). When tested against placebo in an add-on, randomized, double-blind trial, FBM reduced the total seizure frequency of >50% in at least 50% of subjects. FBM appears to be well tolerated. A subsequent open-label follow-up study demonstrated that the improvement has persisted for up to 12 months. Uncontrolled studies indicate that FBM could be effective also in other pediatric epileptic syndromes.

Translated title of the contributionClinical experience with Felbamate in paediatric age
Original languageItalian
Pages (from-to)63-66
Number of pages4
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number86-87
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Clinical experience with Felbamate in paediatric age'. Together they form a unique fingerprint.

Cite this